# Dioseve

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dioseve

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.dioseve.com
- Total disclosed funding: $15M
- Latest round: Series A (Jun 12, 2026)
- Investors on record: 10

## About

Founded in 2021 and based in Tokyo, Japan, Dioseve, Inc., d.b.a Dioseve, a biotechnology startup focuses on creating fertility treatment technologies that utilize induced pluripotent stem (iPS) cells, including products designed to facilitate the maturation of eggs outside the human body for vitro fertilization (IVF) and reduce patient burden. The CEO, Kazuma Kishida, has a background in biotechnology. In June 2026, Dioseve raised JPY 1 billion in?series A funding led by Archetype Ventures, with participation from D4V, SHIONOGI, Pangaea Ventures, DG Daiwa Ventures and MIRAIDOOR.

Dioseve, Inc. specializes in advanced differentiation induction technology that enables the efficient conversion of induced pluripotent stem (iPS) cells into oocytes and ovarian somatic cells. This proprietary technology addresses previously unsolved challenges in reproductive biology and regenerative medicine, providing innovative solutions for applications such as fertility treatments and ovarian function restoration. The company targets a diverse range of stakeholders, including research institutions, healthcare providers, and biotechnology firms, seeking to enhance reproductive health and therapeutic options. Dioseve’s products are positioned within both domestic and international markets, specifically catering to areas such as Japan, the United States, and various regions in Europe, facilitating global access to groundbreaking reproductive technologies.Dioseve generates revenue through partnerships and collaborations with research institutions, healthcare organizations, and biotechnology firms, leveraging its unique technology to create high-value solutions. The company's business model includes direct B2B transactions, wherein clients engage in agreements to utilize Dioseve’s differentiation induction technology for research and clinical applications. Revenue streams are diversified through subscription agreements for ongoing access to their proprietary technologies and services, enabling continuous revenue generation from established partnerships. Specific pricing plans for their flagship products and services reflect the advanced nature of the technology, catering to the specialized needs of their clientele without publicly available pricing details.

The company plans to use the June 2026 funding to commercialize ReproNest and expand its business in Japan and overseas.

## Funding rounds

- Series A, Jun 12, 2026, $6.2M — Pangaea Ventures, Archetype Ventures, MIRAIDOOR, D4V, DG Daiwa Ventures, SHIONOGI
- Series A, Jun 27, 2024, $6.3M — ANRI, Archetype Ventures, MIRAIDOOR, Spiral Capital, DG Daiwa Ventures, QR Investment
- Seed, Aug 18, 2022, $2.9M — ANRI, Coral Capital

## Investors

- ANRI (https://capitalatlas.ai/funds/anri) — Seed, Series A
- Coral Capital — Seed
- Archetype Ventures (https://capitalatlas.ai/funds/archetype-ventures) — Series A
- MIRAIDOOR (https://capitalatlas.ai/funds/miraidoor) — Series A
- Spiral Capital (https://capitalatlas.ai/funds/spiral-capital) — Series A
- DG Daiwa Ventures (https://capitalatlas.ai/funds/dg-daiwa-ventures) — Series A
- QR Investment (https://capitalatlas.ai/funds/qr-investment) — Series A
- Pangaea Ventures (https://capitalatlas.ai/funds/pangaea-ventures) — Series A
- D4V (https://capitalatlas.ai/funds/d4v) — Series A
- SHIONOGI — Series A